Istradefylline Pill

ApprovedSmall molecule

GGeorgetown University

Istradefylline Pill is one of 18 small molecule programs targeting Tremor. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TremorActive, not recruiting

TremorApproved

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Tremor

#DrugCompanyPhaseTrials

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Topamax

1 3

Neurontin

VViatris Specialty LLC

Phase 3

1 4

Xyrem

Jazz Pharmaceuticals

Phase 2

3 5

Epidiolex

Jazz Pharmaceuticals

Phase 2

1 6

XEOMIN

MMerz Pharmaceuticals GmbH

Phase 2

2 7

Onabotulinumtoxin a

Lundbeck

Phase 2

1 8

Alcohol

Astellas

Phase 2

1 9

Istradefylline Pill

GGeorgetown University

Approved

1 10

Abobotulinum Toxin a

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tremor1 trial

Istradefylline Effect Protocol on Parkinson's Disease Tremor

Completed·GGeorgetown University·Phase 4·NCT05885360·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Istradefylline Pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Istradefylline Pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Istradefylline Pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Georgetown University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GGeorgetown University

Istradefylline Pill

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tremor1 trial

References

Drug Info

Quick Facts

Related News